ErbB 2 Pathway Activation upon Smad 4 Loss Promotes Lung Tumor Growth and Metastasis Graphical

[1]  C. Chai,et al.  Role Of TTF‐1, CK20, And CK7 Immunohistochemistry for Diagnosis of Primary and Secondary Lung Adenocarcinoma , 2006, The Kaohsiung journal of medical sciences.

[2]  R. Neve,et al.  ERBB Receptor Regulation of ESX/ELF3 Promotes Invasion in BreastEpithelial Cells , 2010 .

[3]  Takayuki Kosaka,et al.  Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ming-Tsan Lin,et al.  Role of surgical intervention in managing gastrointestinal metastases from lung cancer. , 2011, World journal of gastroenterology.

[5]  Philippe Soriano.  Generalized lacZ expression with the ROSA26 Cre reporter strain , 1999, Nature Genetics.

[6]  Karl J. Dykema,et al.  Cancer-Type Regulation of MIG-6 Expression by Inhibitors of Methylation and Histone Deacetylation , 2012, PloS one.

[7]  A. R. Thitoff,et al.  Conditional deletion of Pten causes bronchiolar hyperplasia. , 2008, American journal of respiratory cell and molecular biology.

[8]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[9]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[10]  T. Mitsudomi,et al.  Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.

[11]  Ester Piek,et al.  Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .

[12]  Shohei Koyama,et al.  Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. , 2014, Cancer cell.

[13]  Zhaoyuan Fang,et al.  Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma , 2014, Nature Communications.

[14]  S. Walker.  Updates in non-small cell lung cancer. , 2008, Clinical journal of oncology nursing.

[15]  A. Berns,et al.  Cell of origin of lung cancer , 2010, Molecular oncology.

[16]  P. Seeburg,et al.  Codon‐improved Cre recombinase (iCre) expression in the mouse , 2002, Genesis.

[17]  I. Wistuba,et al.  The evolving genomic classification of lung cancer , 2013, The Journal of pathology.

[18]  C. Deng,et al.  Generation of Smad4/Dpc4 conditional knockout mice , 2002, Genesis.

[19]  Kristofer C. Berrett,et al.  Sox2 Cooperates with Lkb1 Loss in a Mouse Model of Squamous Cell Lung Cancer , 2014, Cell reports.

[20]  M. Tsao,et al.  Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  T. Hogan,et al.  Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. , 1991, Surgery.

[22]  Hong Wu,et al.  Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. , 2008, Cancer research.

[23]  S. Peters,et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[25]  J. Komorowski,et al.  Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm , 2005, Clinical Cancer Research.

[26]  M. Vangel,et al.  Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Susan E. Wert,et al.  Early restriction of peripheral and proximal cell lineages during formation of the lung , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Ladanyi,et al.  Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas , 2012, Clinical Cancer Research.

[29]  F. DeMayo,et al.  Cre‐mediated recombination in mouse Clara cells , 2008, Genesis.

[30]  Ming-Rong Wang,et al.  Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse. , 2006, Cancer research.

[31]  Yuh-Shan Jou,et al.  Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer , 2005, International journal of cancer.

[32]  L. Wang,et al.  Expression of DPC4/Smad4 in non-small-cell lung carcinoma and its relationship with angiogenesis. , 2008, Neoplasma (Bratislava).

[33]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[34]  F. Liu.  SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res., 7: 4115-4121, 2001. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  S. Sakashita,et al.  Genes and pathology of non-small cell lung carcinoma. , 2014, Seminars in oncology.

[36]  R. Bronson,et al.  Evidence that MIG-6 is a tumor-suppressor gene , 2007, Oncogene.

[37]  M. Meyerson,et al.  The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272 , 2007, Oncogene.

[38]  Toshio Kuroki,et al.  Role of Smad4 (DPC4) inactivation in human cancer. , 2003, Biochemical and biophysical research communications.

[39]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[40]  M. Groszer,et al.  Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene , 2002, Genesis.

[41]  J. Jen,et al.  TGF-&bgr; Signaling and the Role of Inhibitory Smads in Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  Yigong Shi,et al.  A structural basis for mutational inactivation of the tumour suppressor Smad4 , 1997, Nature.

[43]  O. Sansom,et al.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[44]  A. Ullrich,et al.  Mig-6 Is a Negative Regulator of the Epidermal Growth Factor Receptor Signal , 2001, Biological chemistry.

[45]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[46]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[47]  S. Steinberg,et al.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. , 2008, Journal of the National Cancer Institute.

[48]  S. Malkoski,et al.  Role of PTEN in basal cell derived lung carcinogenesis , 2014, Molecular carcinogenesis.

[49]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[50]  T. Mak,et al.  Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. , 2007, The Journal of clinical investigation.

[51]  T. Yoshimatsu,et al.  Long-term survival after surgical resection of liver metastasis from lung cancer. , 2004, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

[52]  Wendy Winckler,et al.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.

[53]  C. Creighton,et al.  COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis , 2012, Nature.